Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

18
results for

"Surgery"

Article category

Keywords

Publication year

"Surgery"

Letters to the Editor

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou
Clin Mol Hepatol 2025;31(3):e252-e253.
Published online February 26, 2025
DOI: https://doi.org/10.3350/cmh.2025.0189
  • 6,529 View
  • 75 Download

Steatotic liver disease

  • 4,630 View
  • 39 Download
  • 6,176 View
  • 52 Download

Reply to Correspondence

Steatotic liver disease

  • 4,355 View
  • 31 Download

Correspondence

Citations

Citations to this article as recorded by  Crossref logo
  • Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
    Jing Zeng, Jian-Gao Fan
    Clinical and Molecular Hepatology.2025; 31(2): e218.     CrossRef
  • 4,684 View
  • 32 Download
  • 1 Web of Science
  • Crossref

Editorial

Steatotic liver disease

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
    Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2025; 31(2): e173.     CrossRef
  • Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
    Jing Zeng, Jian-Gao Fan
    Clinical and Molecular Hepatology.2025; 31(2): e218.     CrossRef
  • 5,613 View
  • 50 Download
  • 2 Web of Science
  • Crossref

Original Article

Steatotic liver disease

Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol 2025;31(1):227-239.
Published online November 14, 2024
DOI: https://doi.org/10.3350/cmh.2024.0564
Background/Aims
With the obesity pandemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and a leading cause of end-stage liver disease and liver-related deaths in the USA. Therefore, we aimed to compare the long-term outcomes of patients with MASLD and cirrhosis with and without bariatric surgery.
Methods
Patients were retrospectively identified from the California Department of Healthcare Access and Information database, 2005 to 2019, for a population-based cohort study. Propensity score matching (PSM) was used to balance background risks between patients with cirrhosis who underwent bariatric surgery and those who did not. Overall, liver-related and non-liver-related mortality were analyzed.
Results
Of 91,708 eligible patients with MASLD and cirrhosis, PSM yielded 2,107 patients who underwent bariatric surgery and 8,428 non-bariatric controls. Compared to matched controls, patients who underwent bariatric surgery had lower 5-year overall (24.9% vs. 37.1%; p<0.0001), liver-related (3.3% vs. 14%; p<0.0001), and non-liver-related mortality (22.3% vs. 26.9%; p=0.046). In multivariable analysis, bariatric surgery was associated with decreased overall mortality (adjusted hazard ratio [aHR]=0.63; p<0.0001), liver-related (aHR=0.24; p<0.0001), and non-liverrelated (aHR=0.81; p=0.0026) mortality. However, only laparoscopic surgeries were associated with lower overall mortality (aHR=0.39; p<0.0001) whereas open surgeries were associated with higher overall mortality (aHR=1.24; p=0.022).
Conclusions
Patients with MASLD and cirrhosis who underwent bariatric surgery, specifically laparoscopic approaches, had significantly lower mortality risk than non-surgical counterparts.

Citations

Citations to this article as recorded by  Crossref logo
  • Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
    Yu Shi, Nicholas Chien, Ashley Fong, Vy H. Nguyen, Surya Teja Gudapati, Angela Chau, Sally Tran, Linda Henry, Ramsey Cheung, Changqing Zhao, Minjuan Jin, Mindie H. Nguyen
    Alimentary Pharmacology & Therapeutics.2025; 61(10): 1622.     CrossRef
  • A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic live
    Jing Zeng, Jian-Gao Fan
    Clinical and Molecular Hepatology.2025; 31(2): 610.     CrossRef
  • Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
    Wei Wang, Yating Xie, Ailei Xu
    Clinical and Molecular Hepatology.2025; 31(2): e143.     CrossRef
  • Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
    Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho
    Trends in Endocrinology & Metabolism.2025; 36(11): 1000.     CrossRef
  • Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
    Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2025; 31(2): e173.     CrossRef
  • Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
    Jing Zeng, Jian-Gao Fan
    Clinical and Molecular Hepatology.2025; 31(2): e218.     CrossRef
  • Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
    Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou
    Clinical and Molecular Hepatology.2025; 31(3): e252.     CrossRef
  • Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018
    Yanshan Yi, Li Yang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
    Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai
    Clinical and Molecular Hepatology.2025; 31(3): e247.     CrossRef
  • Efficacy and Safety of Bariatric Surgery in Well-Compensated Liver Cirrhosis: A Systematic Review and a Single-Arm Meta-analysis
    Pandora Fonseca, Leonardo Pereira, João Gabriel Braga, Giovanna Macanhã Scremin, Luísa de Araujo, Julia Alves, Gabriel de França, Pedro Bregion, Rafael Rego, Maria Farias, Victor Ivano
    Obesity Surgery.2025; 35(10): 4246.     CrossRef
  • Metabolic Dysfunction Associated to Steatotic Liver Disease: A Review
    Janna Vanessa Diaz Torres, Vanessa Rocío Villanueva Guerrero, Jennifer Patricia Vargas Gómez, Fredy Javier Pacheco Miranda, Lorena Rocío Orozco Álvarez, Joseph David León Insignares, Marian Mares, Héctor Mario Rodríguez Ortiz, Evelyn Mendoza-Torres
    Metabolic Syndrome and Related Disorders.2025; 23(10): 427.     CrossRef
  • Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications
    Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas
    Biomedicines.2025; 13(10): 2437.     CrossRef
  • 5,788 View
  • 177 Download
  • 10 Web of Science
  • Crossref

Reviews

Hepatic neoplasm

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, Cheng-Maw Ho, Chun-Jen Liu
Clin Mol Hepatol 2023;29(2):230-241.
Published online January 30, 2023
DOI: https://doi.org/10.3350/cmh.2022.0421
Hepatocellular carcinoma (HCC) is the fourth most common cancer and the second leading cause of cancer-related death in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan developed and updated the guidelines for HCC management in 2020. In clinical practice, we follow these guidelines and the reimbursement policy of the government. In Taiwan, abdominal ultrasonography, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) tests are performed for HCC surveillance every 6 months or every 3 months for high-risk patients. Dynamic computed tomography, magnetic resonance imaging, and contrast-enhanced ultrasound have been recommended for HCC surveillance in extremely high-risk patients or those with poor ultrasonographic visualization results. HCC is usually diagnosed through dynamic imaging, and pathological diagnosis is recommended. Staging of HCC is based on a modified version of the Barcelona Clinic Liver Cancer (BCLC) system, and the HCC management guidelines in Taiwan actively promote curative treatments including surgery and locoregional therapy for BCLC stage B or C patients. Transarterial chemoembolization (TACE), drug-eluting bead TACE, transarterial radioembolization, and hepatic artery infusion chemotherapy may be administered for patients with BCLC stage B or C HCC. Sorafenib and lenvatinib are reimbursed as systemic therapies, and regorafenib and ramucirumab may be reimbursed in cases of sorafenib failure. First-line atezolizumab with bevacizumab is not yet reimbursed but may be administered in clinical practice. Systemic therapy and external beam radiation therapy may be used in specific patients. Early switching to systemic therapy in TACE-refractory patients is a recent paradigm shift in HCC management.

Citations

Citations to this article as recorded by  Crossref logo
  • Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
    Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bai
    European Journal of Cancer.2026; 232: 116109.     CrossRef
  • Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease
    Feng‐Pai Tsai, Tung‐Hung Su, Shang‐Chin Huang, Tai‐Chung Tseng, Shih‐Jer Hsu, Sih‐Han Liao, Chun‐Ming Hong, Chen‐Hua Liu, Hung‐Chih Yang, Chun‐Jen Liu, Pei‐Jer Chen, Jia‐Horng Kao
    Cancer.2025;[Epub]     CrossRef
  • Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Sih-Han Liao, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
    American Journal of Gastroenterology.2025; 120(2): 401.     CrossRef
  • Editorial: PIVKA‐II Facilitates Risk Stratification for HCC Following HCV Cure
    Tung‐Hung Su, Wei‐Chih Liao
    Alimentary Pharmacology & Therapeutics.2025; 61(3): 583.     CrossRef
  • Precision surgery for hepatocellular carcinoma
    Christian Tibor Josef Magyar, Luckshi Rajendran, Zhihao Li, Vanessa Banz, Arndt Vogel, Grainne Mary O'Kane, Albert Chi-Yan Chan, Gonzalo Sapisochin
    The Lancet Gastroenterology & Hepatology.2025; 10(4): 350.     CrossRef
  • Dynamic prognostication and treatment planning for hepatocellular carcinoma: A machine learning-enhanced survival study using multi-centric data
    Lujun Shen, Yiquan Jiang, Linbin Lu, Mengxuan Cui, Jiming Xu, Chen Li, Ruizhi Tang, Qi Zeng, Kai Li, Juan Nie, Jingjun Huang, Boyang Chang, Nan Wu, Feng Shi, Ge Ren, Yao Wang, Zhimei Huang, Chao An, Zhongguo Zhou, Chaofeng Li, Xiong Chen, Letao Lin, Peiho
    The Innovation Medicine.2025; 3(2): 100125.     CrossRef
  • RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma
    Haohao Lu, Ya Gao, Xiangwen Xia, Qing Fu, Dongqiao Xiang
    BMC Cancer.2025;[Epub]     CrossRef
  • Old Dogs Play New Tricks: Alpha-Fetoprotein Dynamics in the Era of GALAD Score
    Tung-Hung Su, Jia-Horng Kao
    Gastroenterology.2025; 169(1): 181.     CrossRef
  • Roadmap for HCC Surveillance and Management in the Asia Pacific
    Masatoshi Kudo, Bui Thi Oanh, Chien-Jen Chen, Do Thi Ngat, Jacob George, Do Young Kim, Luckxawan Pimsawadi, Pisit Tangkijvanich, Raoh-Fang Pwu, Rosmawati Mohamed, Sakarn Bunnag, Sheng-Nan Lu, Sirintip Kudtiyakarn, Tatsuya Kanto, Teerha Piratvisuth, Chao-C
    Cancers.2025; 17(12): 1928.     CrossRef
  • In Situ Vaccination with Poly-ICLC Combined with Systemic Nivolumab for the Treatment of Unresectable Hepatocellular Carcinoma
    Ja-Der Liang, Po-Chin Liang, Chia-Tung Shun, Chien-Hung Chen, Yao-Ming Wu, Yu-Chen Hsu, Ying-Te Lee, Pei-Ming Yang, Guan-Tarn Huang, Andres M Salazar, Hsuan-Shu Lee, Jin-Chuan Sheu, Meng-Tzu Weng
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 1191.     CrossRef
  • Dynamic profiles of early biological responses to predict the treatment efficacy of proton therapy in liver cancer assessed with in vivo kinetic [18F]-FDG PET/MRI
    Yi-Hsiu Chung, I-Chun Cho, Fujie Jhang, Chi-Chang Weng, Gigin Lin, Ching-Fang Yu, Fang-Hsin Chen
    Radiation Oncology.2025;[Epub]     CrossRef
  • Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy
    Pei-Chang Lee, Chi-Jung Wu, I-Cheng Lee, Chieh-Ju Lee, Ming-Chih Hou, Yi-Hsiang Huang
    JHEP Reports.2025; 7(9): 101491.     CrossRef
  • High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease
    Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao
    Clinical and Molecular Hepatology.2025; 31(3): 796.     CrossRef
  • Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial
    Jie Li, Bei Lv, Li Song, Xingxing Zhang, Jian Zhang, Xiaoyi Ding, Yongqiang Liu, Tao Ye, Mengzhou Guo, Tingting Fang, Biwei Yang, Zhiying Zhao, Peixin Huang, Yi Chen, Ningling Ge, Jinglin Xia
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage
    Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • Role of ALBI Grade as a Predictive Factor for Long‐Term Mortality in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Kyoung A Ko, Hyunwoo Oh, Myung Sub Kim, Hyun Pyo Hong, Yong Kyun Cho, Byung Ik Kim, Won Sohn
    Journal of Gastroenterology and Hepatology.2025; 40(11): 2758.     CrossRef
  • Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association
    Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Kim, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim
    Journal of Liver Cancer.2025; 25(2): 140.     CrossRef
  • Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association
    Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Ki, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim
    Annals of Surgical Treatment and Research.2025; 109(3): 123.     CrossRef
  • Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning
    Pei-Chang Lee, Po-Yu Li, Cheng-Yun Lee, Shian-Ren Lin, Chi-Jung Wu, Ya-Wen Hung, Yu-Hua Chen, Jun-Wen Chan, Hsien-Chen Mon, Chieh-Ju Lee, Chen-Ta Chi, I-Cheng Lee, Ming-Chih Hou, Yee Chao, Yi-Hsiang Huang, Jan-Mou Lee
    BMC Cancer.2025;[Epub]     CrossRef
  • Latest advances in hepatocellular carcinoma management and prevention through advanced technologies
    Tamer A. Addissouky, Ibrahim El Tantawy El Sayed, Majeed M. A. Ali, Yuliang Wang, Ayman El Baz, Ahmed A. Khalil, Naglaa Elarabany
    Egyptian Liver Journal.2024;[Epub]     CrossRef
  • Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients
    Hui‐Ling Huang, Te‐Sheng Chang, Lariza Marie Canseco, Fan Wu, Sheng‐Nan Lu
    The Kaohsiung Journal of Medical Sciences.2024; 40(6): 589.     CrossRef
  • Hemoglobin nanoclusters-mediated regulation of KPNA4 in hypoxic tumor microenvironment enhances photodynamic therapy in hepatocellular carcinoma
    Yiliang Wang, Nu Li, Letian Qu, Mu Zhang, Zhuo Li, Xiang Li, Dasheng Cai
    Journal of Nanobiotechnology.2024;[Epub]     CrossRef
  • Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors
    Dao-Han Zhang, Chen Liang, Shu-Yang Hu, Xiao-Yong Huang, Lei Yu, Xian-Long Meng, Xiao-Jun Guo, Hai-Ying Zeng, Zhen Chen, Lv Zhang, Yan-Zi Pei, Mu Ye, Jia-Bin Cai, Pei-Xin Huang, Ying-Hong Shi, Ai-Wu Ke, Yi Chen, Yuan Ji, Yujiang Geno Shi, Jian Zhou, Jia F
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Targeting the p53-p21 axis in liver cancer: Linking cellular senescence to tumor suppression and progression
    Lakshmi Thangavelu, Abdulmalik S.A. Altamimi, Nehmat Ghaboura, M. Arockia Babu, R. Roopashree, Pawan Sharma, Pusparghya Pal, Chhavi Choudhary, G.V. Siva Prasad, Aashna Sinha, Ashok Kumar Balaraman, Sushama Rawat
    Pathology - Research and Practice.2024; 263: 155652.     CrossRef
  • Expression and diagnostic value of abnormal prothrombin and osteopontin in hepatocellular carcinoma with cirrhosis
    Guanjun Li
    American Journal of Translational Research.2024; 16(9): 4688.     CrossRef
  • Calpain 2 promotes Lenvatinib resistance and cancer stem cell traits via both proteolysis-dependent and independent approach in hepatocellular carcinoma
    Xiaolu Ma, Kaixia Zhou, Tianqing Yan, Ling Hu, Suhong Xie, Hui Zheng, Ying Tong, Heng Zhang, Yanchun Wang, Zhiyun Gong, Cuncun Chen, Yanan Tian, Lin Guo, Renquan Lu
    Molecular Biomedicine.2024;[Epub]     CrossRef
  • Efficacy of transcatheter arterial chemoembolization combined with radiotherapy for locally advanced hepatocellular carcinoma
    Lihua Liao
    American Journal of Translational Research.2024; 16(11): 6935.     CrossRef
  • Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
    Shen-Yung Wang
    Clinical and Molecular Hepatology.2023; 29(2): 349.     CrossRef
  • Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(2): 252.     CrossRef
  • Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan
    San-Chi Chen
    Clinical and Molecular Hepatology.2023; 29(2): 352.     CrossRef
  • Viral Status and Treatment Efficacy in Recurrent Hepatocellular Carcinoma After Primary Resection
    Hou-Ying Cheng, Rey-Heng Hu, Chih-Yang Hsiao, Ming-Chih Ho, Yao-Ming Wu, Po-Huang Lee, Cheng-Maw Ho
    Journal of Gastrointestinal Surgery.2023; 27(8): 1594.     CrossRef
  • A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)
    Cong-Cong Wang, Cai-Yan Yu, Jing Zhang, Rui Wang, Xiang-Shuo Kong
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape
    Shamar Young, Jack Hannallah, Dan Goldberg, Tina Sanghvi, Junaid Arshad, Aaron Scott, Gregory Woodhead
    International Journal of Molecular Sciences.2023; 24(14): 11434.     CrossRef
  • Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
    Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim
    Cell Communication and Signaling.2023;[Epub]     CrossRef
  • 13,955 View
  • 435 Download
  • 32 Web of Science
  • Crossref

Steatotic liver disease

Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management
Anja Geerts, Sander Lefere
Clin Mol Hepatol 2023;29(Suppl):S276-S285.
Published online December 22, 2022
DOI: https://doi.org/10.3350/cmh.2022.0373
The prevalence of obesity and metabolic consequences such as nonalcoholic fatty liver diseases (NAFLD) has become a crucial health problem. Lifestyle modifications, especially weight loss, effectively reduces liver injury in NAFLD patients. However, adherence to lifestyle changes is very low in the clinical setting. Bariatric surgery can improve metabolic components and cause long-term weight loss. Therefore, bariatric surgery could serve as an attractive treatment option for NAFLD patients. This review integrates data about the benefits of bariatric surgery on NAFLD but also describes the potential pitfalls.

Citations

Citations to this article as recorded by  Crossref logo
  • Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States
    Brian P. Lam, Jessica Bartholomew, Sherona Bau, HoChong Gilles, Andrea Keller, Ann Moore, Khalil Nader, Lisa Richards, Linda Henry, Zobair M. Younossi
    Journal of Clinical Gastroenterology.2025; 59(4): 298.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
    Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso
    Exploration of Medicine.2025;[Epub]     CrossRef
  • Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes
    Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay, Amerta Ghosh, Seema Gulati, Narendra Singh Choudhary, Deep Dutta, Praveen Sharma, Naval K. Vikram, Ashu Rastogi, Akash Shukla, Alpesh Goyal, Amit Gupta, Anand V. Kulkarni, Anil Chandra Anand, Anil Arora, A
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2025; 19(3): 103209.     CrossRef
  • Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
    Jing Zeng, Jian-Gao Fan
    Clinical and Molecular Hepatology.2025; 31(2): e218.     CrossRef
  • Post-Metabolic Bariatric Surgery Cirrhosis and the Role of Liver Transplantation: A Report from a Referral Transplant Center
    Hamed Nikoupour, Erfan Sheikhbahaei, Alireza Shamsaeefar, Kourosh Kazemi, Mohammad Eslamian, Hamidreza Zefreh, Seyed Ali Malek-Hosseini, Saman Nikeghbalian
    Obesity Surgery.2025; 35(6): 2111.     CrossRef
  • Comparative Analysis of the Incidence of Post-bariatric Cholelithiasis in Sleeve Gastrectomy and Roux-en-Y Gastric Bypass
    Fernando de Barros, Enmanuel Compres Guichardo, Ana Beatriz Monteiro Fonseca, Leonardo Halamy Pereira, Daniel Alejandro Reyes Encalada
    Obesity Surgery.2025; 35(8): 3157.     CrossRef
  • Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Muhammad Moseeb Ali Hashim, Muhammad Aizaz Mohsin Khan, Muhammad Usama Ashraf, Saniya Mohsin, Kamran Zahoor, Javeria Niazi, Aiza Khan, Sania Muzaffar, Madiha Makhdumi, Omar Ahmed Ibad, Talha Kamran Khan, Sohaib Khalid
    Cureus.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
    Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi
    Saudi Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Crotonylation of IDH1 alleviates MASLD progression by enhancing the TCA cycle
    Shanshan Liu, Yu Ji, Luyang Wei, Yiqiao Zhang, Linghang Zeng, Yiyang Min, Danyang Yin, Kun Liu, Chengjian Guan, Shumeng Liu, Huajing Yu, Zhongtao Zhang
    Nature Communications.2025;[Epub]     CrossRef
  • Metabolic Bariatric Surgery for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Scoping Review of Biomarker and Histology Changes
    Aryan Shah, Amirhossein Mohammadi, Adeel Haq, David Walji, Boris Zevin
    Obesity Surgery.2025; 35(10): 4508.     CrossRef
  • Association of Rapid Early Weight Loss with One-Year Hepatic Steatosis Improvement After Sleeve Gastrectomy: A Retrospective Cohort Study
    Min Kyoung Jang, Si Yeol Yoon, Jin A. An, Ji Soo Kim, Min-Seon Kim, Jung Ah Lee, Chang Seok Ko, Se Hee Min
    Journal of Clinical Medicine.2025; 14(20): 7284.     CrossRef
  • Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD
    Yujia Shi
    Hepatology International.2025;[Epub]     CrossRef
  • Mid-term Effects of Bariatric Surgery on Metabolic Dysfunction-Associated Fatty Liver Disease Remission and Predictive Factors: A Prospective Study with a Focus on Non-invasive Diagnosis
    Èlia Navarro-Masip, Núria Mestres, Marta Zorzano-Martínez, Blanca Salinas-Roca, Enric Sánchez, Carolina López-Cano, Fernando Herrerías, Mari Cruz de la Fuente, Maite Santamaría, Josep León-Mengíbar, Ana-Gloria Soler, Marta Bueno, Albert Lecube
    Obesity Surgery.2024; 34(3): 841.     CrossRef
  • Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
    Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo
    Biomedicines.2024; 12(2): 397.     CrossRef
  • Bacteroides and NAFLD: pathophysiology and therapy
    Jun Zhang, Jing Zhou, Zheyun He, Hongshan Li
    Frontiers in Microbiology.2024;[Epub]     CrossRef
  • Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
    Aaron B. Koenig, Albert Tan, Hala Abdelaal, Fanny Monge, Zobair M. Younossi, Zachary D. Goodman
    Alimentary Pharmacology & Therapeutics.2024; 60(2): 167.     CrossRef
  • Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
    Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG
    Chinese Journal of Natural Medicines.2024; 22(8): 724.     CrossRef
  • The Role of Preoperative Abdominal Ultrasound in the Preparation of Patients Undergoing Primary Metabolic and Bariatric Surgery: A Machine Learning Algorithm on 4418 Patients’ Records
    Mohamed Hany, Mohamed El Shafei, Mohamed Ibrahim, Ann Samy Shafiq Agayby, Anwar Ashraf Abouelnasr, Moustafa R. Aboelsoud, Ehab Elmongui, Bart Torensma
    Obesity Surgery.2024; 34(9): 3445.     CrossRef
  • Cytokeratin 18 in nonalcoholic fatty liver disease: value and application
    Yuan Wu, Jing Zhou, Jun Zhang, Hongshan Li
    Expert Review of Molecular Diagnostics.2024; 24(11): 1009.     CrossRef
  • Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study
    José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente
    Nutrients.2024; 16(22): 3857.     CrossRef
  • Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients
    Álvaro Pérez-Rubio, Polina Soluyanova, Erika Moro, Guillermo Quintás, Iván Rienda, María Dolores Periañez, Andrés Painel, José Vizuete, Judith Pérez-Rojas, José V. Castell, Ramón Trullenque-Juan, Eugenia Pareja, Ramiro Jover
    Nutrients.2023; 15(14): 3187.     CrossRef
  • 8,255 View
  • 167 Download
  • 19 Web of Science
  • Crossref

Case Report

Hepatic neoplasm

A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult
Keun Woo Park, Chang Jin Seo, Dae Young Yun, Min Keun Kim, Byung Seok Kim, Young Seok Han, Hoon Kyu Oh, Chang Hyeong Lee
Clin Mol Hepatol 2015;21(3):300-308.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.300

Hepatoblastoma usually occurs in children under the age of 2 years, with very few cases reported in adults. We experienced a case of adult hepatoblastoma in a 36-year-old female with chronic hepatitis B. She had experienced sudden onset abdominal pain. Her serum alpha-fetoprotein level was markedly elevated, and abdominal CT showed a 9-cm mass with internal hemorrhage in the right hepatic lobe with hemoperitoneum, so an emergency hepatic central bisectionectomy was performed. The initial histologic examination revealed that the mass mimicked combined hepatocellular carcinoma and cholangiocarcinoma with spindle-cell metaplasia of the cholangiocarcinoma element. Follow-up abdominal CT performed 3 months later showed a 5.5-cm metastatic mass in the left subphrenic area. Laparoscopic splenectomy with mass excision was performed, and hepatoblastoma was confirmed histologically. A histologic re-examination of previously obtained surgical specimens also confirmed the presence of hepatoblastoma. Metastatic hepatoblastoma was found at multiple sites of the abdomen during follow-up, and so chemotherapy with cisplatin, 5-fluorouracil (5-FU), and vincristine was applied, followed by carboplatin and doxorubicin. Despite surgery and postoperative chemotherapy, she died 12 months after symptom onset.

Citations

Citations to this article as recorded by  Crossref logo
  • Adult Hepatoblastoma and Concomitant Hepatitis B Infection
    Alejandro Nieto Dominguez, Sarah Elizabeth Eichinger, Elza Matrova, Anas Almoghrabi
    ACG Case Reports Journal.2024; 11(9): e01491.     CrossRef
  • Blastomas of the digestive system in adults: A review
    Yu Liu, Tony El Jabbour, Jonathan Somma, Yukihiro Nakanishi, Saverio Ligato, Hwajeong Lee, Zhi-Yan Fu
    World Journal of Gastrointestinal Surgery.2024; 16(4): 1030.     CrossRef
  • Coexistence of primary clear cell subtype of hepatocellular carcinoma, cholangiocarcinoma, and ordinary type hepatocellular carcinoma: A case report
    Jian Xu, Xiang-yu Lu, Yu Zhang, Xiao-jiong Yu, Juan Li, Hao Zhang
    International Journal of Surgery Case Reports.2023; 112: 109002.     CrossRef
  • Hepatoblastoma in a Young Adult: a Rare Case Report and Review of the Literature
    Jeewan Ram Vishnoi, Ajai Sasidhar, Sanjeev Misra, Puneet Pareek, Sudeep Khera, Sushil Kumar, Ankit Jain
    Journal of Gastrointestinal Cancer.2020; 51(1): 319.     CrossRef
  • Hepatoblastoma with pure fetal epithelial differentiation in a 10-year-old boy
    Shanshan Zhong, Yang Zhao, Chuifeng Fan
    Medicine.2018; 97(2): e9647.     CrossRef
  • Two Cases of Hepatoblastoma in Young Adults
    Karel de Bree, Anneke M. Westermann, Heinz-Josef Klümpen, Joanne Verheij, Saffire S.K.S. Phoa, Matthijs Oomen, Thomas M. van Gulik
    Journal of Adolescent and Young Adult Oncology.2018; 7(3): 404.     CrossRef
  • Hepatoblastoma incidence in Taiwan: A population-based study
    Giun-Yi Hung, Li-Yih Lin, Ting-Yen Yu, Chih-Ying Lee, Hsiu-Ju Yen, Jiun-Lin Horng
    Journal of the Chinese Medical Association.2018; 81(6): 541.     CrossRef
  • Hepatocellular malignant neoplasm, NOS: a clinicopathological study of 11 cases from a single institution
    Shengmei Zhou, Rajkumar Venkatramani, Shveta Gupta, Kasper Wang, James E Stein, Larry Wang, Leo Mascarenhas
    Histopathology.2017; 71(5): 813.     CrossRef
  • Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis
    Feng Zhang, Chun‑Mei Zhang, Shu Li, Kun‑Kun Wang, Bin‑Bin Guo, Yao Fu, Lu‑Yang Liu, Yu Zhang, Hai‑Yu Jiang, Chang‑Jun Wu
    Molecular Medicine Reports.2017;[Epub]     CrossRef
  • Imaging of Rare Primary Malignant Hepatic Tumors in Adults With Histopathological Correlation
    Abhijit Sunnapwar, Rashmi Katre, Maria Policarpio-Nicolas, Venkata Katabathina, Marc Erian
    Journal of Computer Assisted Tomography.2016; 40(3): 452.     CrossRef
  • Uncommon liver tumors
    Chia-Hung Wu, Nai-Chi Chiu, Yi-Chen Yeh, Yu Kuo, Sz-Shian Yu, Ching-Yao Weng, Chien-An Liu, Yi-Hong Chou, Yi-You Chiou
    Medicine.2016; 95(39): e4952.     CrossRef
  • 14,296 View
  • 132 Download
  • 11 Web of Science
  • Crossref
Original Articles
Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis
Woo Jin Lee, Hong Joo Kim, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Korean J Hepatol 2011;17(4):292-298.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.292
Background/Aims

Hepatic hydrothorax in patients with decompensated liver cirrhosis is a challenging problem. Treatment with diuretics and intermittent thoracentesis can be effective in selected patients. However, there are few effective therapeutic options in patients who are intolerant of these therapies. This study investigated the clinical usefulness of chemical pleurodesis with or without video-assisted thoracoscopic surgery (VATS) for patients with refractory hepatic hydrothorax.

Methods

Eleven consecutive patients with refractory hepatic hydrothorax who underwent chemical pleurodesis with or without VATS between July 2007 and February 2011 were enrolled in this study. The medical records and radiologic imagings of these patients were thoroughly reviewed.

Results

The median number of chemical pleurodesis sessions performed was 3 (range: 2-10). Successful pleurodesis was achieved in 8 of the 11 patients (72.7%), 5 (62.5%) of whom remained asymptomatic and hydrothorax free for a median follow-up of 16 weeks (range: 2-52 weeks). Complications were low-grade fever/leukocytosis (n=11, 100%), pneumonia (n=1, 9.1%), pneumothorax (n=4, 36.4%), azotemia/acute renal failure (n=6, 54.6%), and hepatic encephalopathy (n=4, 36.4%). Five patients were suspected as having procedure-related mortality (45.5%) due to the occurrence of acute renal failure with hepatic failure. The overall survival was significantly longer in the success group than in the non-success group.

Conclusions

Although chemical pleurodesis may improve the clinical symptoms and the radiologic findings in as many as 72.7% of patients with refractory hepatic hydrothorax, a significantly high prevalence of procedure-related morbidity and mortality hinders the routine application of this procedure for such patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Effective Management of Refractory Hepatic Hydrothorax With Hypertonic Glucose Pleurodesis
    Shuya Hashimoto, Toyoshi Yanagihara, Natsumi Kushima, Rei Sanai, Takato Ikeda, Naoki Hamada, Masaki Fujita
    Cureus.2025;[Epub]     CrossRef
  • Hepatic hydrothorax as a manifestation of decompensated cirrhosis: An update on current management and future directions
    Brandon-Joe Cilia, James Haridy, Ashok Raj, Nicholas Hannah
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Effectiveness of Chemical Pleurodesis Using Doxycycline in Malignant and Nonmalignant Pleural Disorders: A Retrospective Study from Rural South India
    Bimal Raj Rajalingam, Priya R Panicker, Archana L Peethambaran, Alexander Jenish Babu, Ravichandran Vijayakumar
    Indian Journal of Respiratory Care.2024; 12(4): 299.     CrossRef
  • Pleural Port-A-Cath for Symptomatic Refractory Hepatic Hydrothorax in Nontransplant Liver Patients
    Khaled Alshabani, Estefania Rivera, Alichia Paton, Juan Camilo Lara, Sebastian Fernandez-Bussy, Adnan Majid
    Annals of the American Thoracic Society.2024; 21(5): 823.     CrossRef
  • Medical thoracoscopy with talc pleurodesis for refractory hepatic hydrothorax: A case series of three successes
    Y. Rahim, R.V. Reddy, M. Naeem, G. Tsaknis
    Respiratory Medicine Case Reports.2024; 50: 102039.     CrossRef
  • ERS statement on benign pleural effusions in adults
    Anand Sundaralingam, Elzbieta M. Grabczak, Patrizia Burra, M. Inês Costa, Vineeth George, Eli Harriss, Ewa A. Jankowska, Julius P. Janssen, Georgia Karpathiou, Christian B. Laursen, Kornelija Maceviciute, Nick Maskell, Federico Mei, Blin Nagavci, Vasiliki
    European Respiratory Journal.2024; 64(6): 2302307.     CrossRef
  • Pulmonary complications of portal hypertension: The overlooked decompensation
    Rares Craciun, Tudor Mocan, Bogdan Procopet, Andrada Nemes, Cristian Tefas, Mihaela Sparchez, Lavinia-Patricia Mocan, Zeno Sparchez
    World Journal of Clinical Cases.2022; 10(17): 5531.     CrossRef
  • Modified indwelling pleural catheter versus silver nitrate pleurodesis for the management of malignant pleural effusion
    Mohammed F. Abdelghany, Khaled Essmat, Atef Farouk El-Karn, Sahar Farghly Youssif
    The Egyptian Journal of Chest Diseases and Tuberculosis.2022; 71(2): 248.     CrossRef
  • Hepatic Hydrothorax—An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis
    Daniela Matei, Rares Craciun, Dana Crisan, Bogdan Procopet, Tudor Mocan, Sergiu Pasca, Roxana Zaharie, Bogdan Popovici, Zeno Sparchez
    Journal of Clinical Medicine.2021; 10(16): 3688.     CrossRef
  • Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance
    Bubu A. Banini, Yahya Alwatari, Madeline Stovall, Nathan Ogden, Evgeni Gershman, Rachit D. Shah, Brian J. Strife, Samira Shojaee, Richard K. Sterling
    Hepatology.2020; 72(5): 1851.     CrossRef
  • Hepatic Hydrothorax: An Updated Review on a Challenging Disease
    Toufic Chaaban, Nadim Kanj, Imad Bou Akl
    Lung.2019; 197(4): 399.     CrossRef
  • Hepatic Hydrothorax
    Yong Lv, Guohong Han, Daiming Fan
    Annals of Hepatology.2018; 17(1): 33.     CrossRef
  • Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion
    Mohammad K. El Badrawy, Raed El-Metwally Ali, Asem A. Hewidy, Mohamed A. El-Layeh, Fatma M. F. Akl, Abdelhadi Shebl
    Egyptian Journal of Bronchology.2018; 12(1): 98.     CrossRef
  • Diagnóstico y manejo de los trasudados pleurales
    Lucía Ferreiro, José M. Porcel, Luis Valdés
    Archivos de Bronconeumología.2017; 53(11): 629.     CrossRef
  • Diagnosis and Management of Pleural Transudates
    Lucía Ferreiro, José M. Porcel, Luis Valdés
    Archivos de Bronconeumología (English Edition).2017; 53(11): 629.     CrossRef
  • Chemical pleurodesis by small bore catheter in hepatic hydrothorax: A feasibility study
    Asem A. Hewidy, Nasef Abdelsalam A. Rezk, Ahmed Abdel-Razik
    Egyptian Journal of Chest Diseases and Tuberculosis.2016; 65(1): 187.     CrossRef
  • Pigtail Catheter: A Less Invasive Option for Pleural Drainage in Egyptian Patients with Recurrent Hepatic Hydrothorax
    Mohamed Sharaf-Eldin, Adel Salah Bediwy, Abdelrahman Kobtan, Sherief Abd-Elsalam, Ferial El-Kalla, Loai Mansour, Walaa Elkhalawany, Mohamed Elhendawy, Samah Soliman
    Gastroenterology Research and Practice.2016; 2016: 1.     CrossRef
  • Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis
    Feifei Hou, Xingshun Qi, Xiaozhong Guo
    Digestive Diseases and Sciences.2016; 61(11): 3321.     CrossRef
  • Hepatic hydrothorax: clinical review and update on consensus guidelines
    Rana Khazar Al-Zoubi, Mouhanna Abu Ghanimeh, Ashraf Gohar, Gary A. Salzman, Osama Yousef
    Hospital Practice.2016; 44(4): 213.     CrossRef
  • The management of benign non-infective pleural effusions
    Oliver J. Bintcliffe, Gary Y.C. Lee, Najib M. Rahman, Nick A. Maskell
    European Respiratory Review.2016; 25(141): 303.     CrossRef
  • Ultrasound-guided pleurodesis with doxycycline in patients with hepatic hydrothorax
    Ahmed M. Abd El Hafeez, Waleed F. Fathallah
    Egyptian Journal of Bronchology.2016; 10(1): 20.     CrossRef
  • Efficacy of nonsurgical tigecycline pleurodesis for the management of hepatic hydrothorax in patients with liver cirrhosis
    Nevin Yilmaz, Arife Zeybek, Benjamin Tharian, Ugur Eser Yilmaz
    Surgical Case Reports.2015;[Epub]     CrossRef
  • Three hepatocellular carcinoma patients with pleural effusion successfully treated by pleurodesis with a view to palliative medicine
    Junichi Senoo, Tetsuhiro Chiba, Tomoko Saito, Yoshihiko Ooka, Sadahisa Ogasawara, Hirotaka Koseki, Naoya Kanogawa, Eiichiro Suzuki, Akinobu Tawada, Osamu Yokosuka
    Kanzo.2015; 56(5): 213.     CrossRef
  • Management of refractory hepatic hydrothorax
    José M. Porcel
    Current Opinion in Pulmonary Medicine.2014; 20(4): 352.     CrossRef
  • Hepatic Hydrothorax
    John Paul Norvell, James R. Spivey
    Clinics in Liver Disease.2014; 18(2): 439.     CrossRef
  • Indwelling pleural catheters for benign pleural effusions
    O. J. Bintcliffe, D. T. Arnold, N. A. Maskell
    Current Respiratory Care Reports.2014; 3(2): 61.     CrossRef
  • Symptomatic hepatic hydrothorax successfully treated with transjugular intrahepatic portosystemic shunt (TIPS)–role of titration of portosystemic gradient reduction to avoid post‐TIPS encephalopathy
    T. L. Krishnamoorthy, M. Taneja, P. E. Chang
    Clinical Case Reports.2014; 2(3): 93.     CrossRef
  • Hidrotórax de causa hepática: análisis de 77 pacientes
    José M. Porcel, Estela Mas, Josep M. Reñé, Silvia Bielsa
    Medicina Clínica.2013; 141(11): 484.     CrossRef
  • Paradigms in the management of hepatic hydrothorax: past, present, and future
    Sachin Kumar, Shiv Kumar Sarin
    Hepatology International.2013; 7(1): 80.     CrossRef
  • Evidence-Based Review of the Management of Hepatic Hydrothorax
    Amita Singh, Abubakr Bajwa, Adil Shujaat
    Respiration.2013; 86(2): 155.     CrossRef
  • 11,122 View
  • 64 Download
  • Crossref
Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma
Ja Young Kang, Moon Seok Choi, Sue Jin Kim, Jae Sook Kil, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
Korean J Hepatol 2010;16(4):383-388.
Published online December 31, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.4.383
Background/Aims

Transarterial chemoembolization (TACE) improves the survival of patients with unresectable hepatocellular carcinoma (HCC) and has been recommended as a first-line therapy for nonsurgical patients with large or multifocal HCC. The long-term outcome of HCC patients receiving TACE prior to hepatic resection is uncertain.

Methods

Between January 1997 and December 2007, 1,530 patients underwent hepatic resection for HCC at our center. Thirty-two patients received 1~12 sessions of TACE followed by surgical resection (TACE-surgery group). Their overall and recurrence-free survival rates were compared with those of 64 age- and sex-matched controls who underwent surgery only (surgery group). Overall and recurrence-free survival rates were analyzed.

Results

The 1-, 2-, and 5-year overall survival rates did not differ significantly between the TACE-surgery group and the surgery group (78%, 60%, and 26%, respectively, vs. 97%, 83%, and 45%, respectively; P=0.11); however, the 1-, 2-, and 5-year recurrence-free survival rates were significantly lower in the TACE-surgery group than in the surgery group (58%, 36%, and 7%, respectively, vs. 77%, 58%, and 32%, respectively; P=0.01). The distribution of recurrence sites in the TACE-surgery group were intrahepatic in 85.7% and extrahepatic in 14.3%, and did not differ from those in the surgery group (91.4% and 8.6%, respectively; P=0.66).

Conclusions

HCC patients who underwent TACE before resection appear to have overall survival rates that are comparable to those without preoperative therapy, although recurrence rates appear to be higher in patients with TACE.

Citations

Citations to this article as recorded by  Crossref logo
  • Patterns of Site and Timing of Recurrence After Curative Resection in Single and Multiple Large Hepatocellular Carcinoma: A Multicenter International Comprehensive Analysis
    Fabio Giannone, Gianluca Cassese, Antonio Cubisino, Emanuele Felli, Federica Cipriani, Bruno Branciforte, Rami Rhaiem, Alessandro Tropea, Edoardo Maria Muttillo, Andrea Scarinci, Bader Al Taweel, Raffaele Brustia, Ephrem Salame, Daniele Sommacale, Salvato
    Annals of Surgical Oncology.2025; 32(9): 6312.     CrossRef
  • Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis
    Run Hu, Jie Xu, Hongxiang Wang, Jiaguo Wang, Kai Lei, Xiaoping Zhao, Huizhi Zhang, Ke You, Zuojin Liu
    BMC Cancer.2024;[Epub]     CrossRef
  • Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis
    Ya-nan Ma, Xuemei Jiang, Peipei Song, Wei Tang
    BioScience Trends.2024; 18(1): 21.     CrossRef
  • Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors
    Junichi Arita, Akihiko Ichida, Rihito Nagata, Yuichiro Mihara, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa
    Journal of Hepato-Biliary-Pancreatic Sciences.2022; 29(7): 732.     CrossRef
  • Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit
    Zhan-Qi Wei, Yue-Wei Zhang
    Chinese Medical Journal.2021; 134(19): 2275.     CrossRef
  • Neutrophil-lymphocyte ratio predicts the therapeutic benefit of neoadjuvant transarterial chemoembolization in patients with resectable hepatocellular carcinoma
    Young Mi Hong, Mong Cho, Ki Tae Yoon, Je Ho Ryu, Kwang Ho Yang, Ung Bae Jeon, Tae Ho Hwang
    European Journal of Gastroenterology & Hepatology.2020; 32(9): 1186.     CrossRef
  • Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study
    Yi-Sheng Liu, Chia-Ying Lin, Ming-Tsung Chuang, Yi-Shan Tsai, Chien-Kuo Wang, Ming-Ching Ou
    Clinics and Research in Hepatology and Gastroenterology.2018; 42(6): 542.     CrossRef
  • Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma
    Yi-Sheng Liu, Chia-Ying Lin, Ming-Tsung Chuang, Chia-Ying Lin, Yi-Shan Tsai, Chien-Kuo Wang, Ming-Ching Ou
    BMC Gastroenterology.2018;[Epub]     CrossRef
  • Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization
    Hongyuan Liang, Peng Cui, Qiyong Guo, Xiaonan Mao, Feng Wen, Wei Sun, Ming Shan, Zaiming Lu
    Asia-Pacific Journal of Clinical Oncology.2017;[Epub]     CrossRef
  • Hepatocellular carcinomas with intracellular hyaline bodies have a poor prognosis
    Ariane Aigelsreiter, Jens Neumann, Martin Pichler, Judith Halasz, Kurt Zatloukal, Andrea Berghold, Philipp Douschan, Florian Rainer, Rudolf Stauber, Johannes Haybaeck, Helmut Denk, Carolin Lackner
    Liver International.2017; 37(4): 600.     CrossRef
  • Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma
    Lei Jianyong, Zhong Jinjing, Yan Lunan, Zhu Jingqiang, Wang Wentao, Zeng Yong, Li Bo, Wen Tianfu, Yang Jiaying
    Scientific Reports.2017;[Epub]     CrossRef
  • Complete Remission after Sequential Therapy of Drug Eluting Beads Transarterial Chemoembolization and Liver Resection in Large Solitary Nodule Hepatocellular Carcinoma
    Juferdy Kurniawan, Andri Sanityoso Sulaiman, Sahat Basana Romanti Ezer Matondang, Toar Jean Maurice Lalisang, Ening Krisnuhoni, Steven Zulkifly
    Case Reports in Hepatology.2017; 2017: 1.     CrossRef
  • Response to transarterial chemoembolization as a selection criterion for resection of hepatocellular carcinomas
    J Y Lei, J J Zhong, L N Yan, J Q Zhu, W T Wang, Y Zeng, B Li, T F Wen, J Y Yang
    British Journal of Surgery.2016; 103(7): 881.     CrossRef
  • Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis
    Xingshun Qi, Lei Liu, Diya Wang, Hongyu Li, Chunping Su, Xiaozhong Guo
    Oncotarget.2015; 6(34): 36838.     CrossRef
  • Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma
    Weiguang Xu, Jung-Hee Kwon, Young Ho Moon, Young Bae Kim, Yun Suk Yu, Namgyu Lee, Kwan Yong Choi, Yun Soo Kim, Yong Keun Park, Bong Wan Kim, Hee Jung Wang
    Journal of Cancer Research and Clinical Oncology.2014; 140(9): 1507.     CrossRef
  • Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis
    Lei Jianyong, Zhong Jinjing, Wang Wentao, Yan Lunan, Zhou Qiao, Li Bo, Wen Tianfu, Xu Minqing, Yang Jiaying, Wei Yongang
    Annals of Hepatology.2014; 13(4): 394.     CrossRef
  • Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma
    Yanming Zhou, Xiaofeng Zhang, Lupeng Wu, Feng Ye, Xu Su, Lehua Shi, Bin Li
    BMC Gastroenterology.2013;[Epub]     CrossRef
  • Indocyanine green clearance in evaluating the recovery of liver reserve function after superselective transarterial chemoembolization
    Xin Chen, Hai-Bing Zhang, Zhong-Qi Li, Xiong-Fei Yu, Mei-Fang Yang, Hao-Hao Wang, Li-Song Teng
    Hepatobiliary & Pancreatic Diseases International.2013; 12(6): 656.     CrossRef
  • Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review
    Theresa R. Harring, N. Thao N. Nguyen, John A. Goss, Christine A. O'Mahony
    International Journal of Hepatology.2011; 2011: 1.     CrossRef
  • 10,349 View
  • 74 Download
  • Crossref
Treatment outcome of the patients with small hepatoma ( ≤ 5 cm in diameter ) in relation to treatment modalities and underlying liver function
Kun Hoon Song , Kwang Hyub Han , Young Myung Moon , Chae Yoon Chon , Won Choi , Kwan Sik Lee , In Suh Park , Byong Ro Kim , Jong Tae Lee
Korean J Hepatol 1996;2(2):186-197.
Background/Aims
. To compare treatment outcome of hepatocellular carcinoma(HCC) under the size of 5 cm in relation to underlying liver function and treatment modalities, analysis of data from 145 patients was performed. Methods '. In this study, the records of 145 patients with small HCC (< 5 cm in diameter determined by hepatic angiography) were reviewed. Clinical parameters were analyzed and survival rate, recurrence rate were calculated. Results '. There were 107(73.8%) men and 38 women. Mean age at diagnosis was 55.1(range .' 25 83 year-old). HBsAg was detected in 97(66.9%) patients. Seventy two(50.0%) patients showed markedly elevated(>40 ng/mL) serum alpha-fetoprotein(AFP) level. Liver cirrhosis was associated in 109(75.2%) patients. Sixty five(44.8%) patients underwent surge, 63(43.5%) underwent transarterial therapy(TAT), 8(5.5%) underwent other modalities of therapy and the remaining 9(6.2% ) patients did not receive any specific treatment for HCC. In relation to the underlying liver function, 119(82.1% ) patients belonged to the non-cirrhotic or Child-Pugh class A, 20(13.8%) to class B and 6(4.1%) to class C. The median follow-up duration was 21 months. When analyzed with respect to treatment modalities alone, median survival was 43 months for all patients, 60 months for surgery, 29 months for TAT, 20 months for other treatment and 18 months for patients who received no specific treatment. Without considering liver function, cumulative 3 year survival rate was 68.6% for surgery, 43.9% for TAT, 29.2% for other treatment and 0% for no treatment. The survival rate for the patients who underwent surgery was significantly higher than for any other treatment modalities without considering the underlying liver function or in the non-cirrhotic/Child-Pugh class A(p<0.001). In patients whose tumor size was equal to or less than 3 cm, there was no difference in survival rate in relation to the treatment modalities when not considering the underlying liver function of each patient(p>0.05). But in patients classified as the non-cirrhotic/Child-Pugh class A, better survival was observed in the surgep group than the TAT group(p<0.05). The only factor influencing survival was the pre-treatment serum AFP level(p<0.05). The overall recurrence rate was 30.3%. For the entire patients, the factor significantly influencing the recurrence rate was the presence of underlying cirrhosis. When considering only the patients in the surgery group, the different types of surgical procedures significantly influenced the recurrence rate. Conclusion .' Surgery is the treatment of choice for patients with HCC equal to or smaller than 5 cm. But for those patients whose tumor size is less than 3 cm, TAT may be a reasonable alternative to surgep when the liver function is not adequate for hepatic resection. Because overall recurrence rate exceeded 30% and median time of recurrence was only 9.5 months after definitive treatment, careful follow-up is required for all patients who undergo treatment for small HCC.
  • 65,535 View
  • 13 Download
Usefulness of Combined CTAP and CTHA as a Preoperative Study of Hepatocellular Carcinoma
Suk Ho Lee , Joon Hyoek Lee , Kwang Cheol Koh , Seung Woon Paik , Jong Kyun Lee , Kyu Taek Lee , In Koo Kang , Sung Yun Oh , Poong Lyul Rhee , Jae Jun Kim , Jong Chul Rhee
Korean J Hepatol 1997;3(4):329-336.
Background/Aims
Combined computed tomography during arterial portography(CfAP) and computed tomography during hepatic arteriography(CBiA) are more sensitive methods compared to conventional spiral CT in detecting small hepatocellular carcinoma. However, there are few data available on the influence of combined CTAP and CTHA on decision making for treatment of hepatocellular carcinoma. We aimed to evaluate the usefulness of CTAP and CfHA as a preoperative study of hepatocellular carcinoma for surgical treatment. Methods: Eighty-two patients with histologically proven hepatocellular carcinoma who were considered to be surgical candidates on spiral CT and angiography were included. CfAP and CTHA were performed as the routine protocol. The findings of CTAP and CTHA were analyzed and compared to conventianal spiral Cl and angiography. Results: 1) 105 nodules were found on spiral Cf plus angiography, whereas, 138 nodules found on combined CIAP and CTHA: 33 additional nodules were found in 23 cases(28%). 2) The treatment plan changed from surgery to nonsurgical treatment in 10(12%) cases: 9 cases(10%) with bilobar involvement, and 1 case (1%) with more than three nodules. 3) The larger the tumor nodules on the spiral CT, the more additional tumor nodules were found on CTAP and CTHA: combined CTAP and CTHA were able to find more nodules in 21% of tumor < 3cm, 27% of tumor with 3 - 10cm, and 71% of tumor >10cm on spiral CI' (p=0.03). Conclusion Compared to spiral CT plus angiography, CI'AP and CfHA may be useful in avoiding unnecessary operation of hepatocellular carcinoma, especially in large tumors. (Korean J Hepatol 1997;7:329 336)
  • 3,068 View
  • 20 Download
Difference in Early Postoperative Recurrence Rate of Hepatocellular Carcinoma According to the Imaging Modalities Used for Preoperative Staging : Comparison Between CTAP and CTHA, Lipiodol CT and Three Phase Helical CT
Moon Seok Choi, Seung Woon Paik, Sang Goo Lee, Joon Hyoek Lee, Kwang Cheol Koh, Poong Lyul Rhee, Jae Jun Kim, Jong Chul Rhee and Kyoo Wan Choi
Korean J Hepatol 1998;4(4):358-364.
Background
/ Aims : Computed tomography during arterial portography and computed tomography during hepatic arteriography (CTAP and CTHA), one of the most sensitive method in detection of hepatocellular carcinoma (HCC) nodules , is reported to reduce unnecessary operation of HCC. However, it is not clear whet her CT AP and CT HA can reduce early post operative recurrence rate of HCC. We performed this study to find any differences in early postoperative recurrence rate of HCC according to the imaging modalities used for preoperativest aging. Methods : Ninety- seven patients with HCC who had underg one curative hepat icres ection from Dec.1994 to Mar . 1998 were included (median age = 52 years (26 - 78), M:F = 85:12). They were classified into 3 groups according to the imaging methods used for preoper ative staging: CTAP & CTHA group (n=56), Lipiodol CT group (n=24), and three phase helical CT group (n=16). No significant inter-group difference was found in preoperative status of the patients or characteristics of HCC. One-year recurrence rates were compared by log- rank test . Results : HCC recurred in 17 of 97 patients (18.7%) within 12 months. A significant difference in 1- year recurrence rate was observed between the groups: helical CT , may be a superior imaging modality for preoperative staging of HCC that can reduce early postoperative recurrence rate. (Korean J Hepatol 1998;4:358 364)
  • 2,760 View
  • 14 Download
Clinical Outcome of Pulmonary Resections in Patients with Pulmonary Metastasis of Hepatocellular Carcinoma
Kyung Kyu Kim, M.D., Ja Kyung Kim, M.D., Do Young Kim, M.D., Sang Hoon Ahn, M.D., Chae Yoon Chon, M.D., Young Myoung Moon, M.D., Kyung Young Chung, M.D.1 and Kwang-Hyub Han, M.D.
Korean J Hepatol 2005;11(4):350-358.
Background/Aims
Although the lung is the most common site of extrahepatic spread from hepatocellular carcinoma (HCC), the role of surgery for pulmonary metastasis remains unclear. The aim of this study was to evaluate the efficacy of pulmonary resection in patients with pulmonary metastasis from HCC. Methods: Between July 2000 and July 2004, a total of 6 patients with pulmonary metastasis from HCC underwent curative pulmonary resections. The patients were divided into two groups (Surgery group and Non-surgery group) according to the primary treatment modality of HCC. Medical records, imaging studies, and pathologic reports of the surgical specimens were reviewed. Results: Three patients in the surgery group underwent pulmonary resections for a solitary metastasis after hepatectomy for HCC, and they are all still alive. One of the 3 patients developed a tumor recurrence in the chest wall after pulmonary resection. The survival time after diagnosis of HCC were 79, 122, and 54 months, respectively. The survival time after pulmonary metastatectomy were 49, 39, and 20 months in the three patients. Another 3 patients in the non-surgery group, received a pulmonary metastatectomy; they had either a complete response HCC or partial radiologic response. These 3 patients developed recurrent disease in the liver. One of 3 patients died. The survival time after diagnosis of HCC were 153, 83, 12 months. The survival time after pulmonary metastatectomy were 51, 4, 2 months. Conclusions: The surgical resections of a solitary pulmonary metastasis from HCC in highly selected patients might be an effective treatment modalities for prolonged survival. (Korean J Hepatol 2005;11:350-358)
  • 3,704 View
  • 20 Download
The Adverse Effect of Indirectly Diagnosed Portal Hypertension on the Complications and Prognosis after Hepatic Resection of Hepatocellular Carcinoma
Min An , Joong Won Park , Jeong A Shin , Joon Il Choi , Tae Hyun Kim , Seong Hoon Kim , Woo Jin Lee , Sang Jae Park , Eun Kyoung Hong , Chang Min Kim
Korean J Hepatol 2006;12(4):553-561.
Backgrounds/Aims
Surgical resection is considered as a curative treatment modality for patient with hepatocellular carcinoma (HCC). Since HCC often occurs in chronic liver disease, selecting optimal candidates based on the hepatic function reserve and the risk of hepatic decompensation after resection is important. In recent studies, clinically relevant portal hypertension including hepatic venous pressure gradient (HVPG) is considered as the best predictor of postoperative hepatic decompensation. However, since measuring HVPG requires an invasive procedure it is not widely used in practice. We aimed to evaluate whether the portal hypertension diagnosed indirectly could be a useful parameter for predicting postoperative prognosis. Methods: A total of 142 patients with HCC who had endoscopic examination, computed tomography and surgical resection from January 2001 to June 2004 were included in the study. We diagnosed portal hypertension indirectly by the presence of varices or splenomegaly with thrmobocytopenia. Postoperative complications and survival rate according to the presence of portal hypertension was studied. Results: The postoperative morbidity rate was 42.2%. The incidence of ascites and prolonged hyperbilirubinemia were significantly higher in portal hypertension group (ascites 43.8 vs. 10.3%, hyperbilirubinemia 20.3 vs. 1.3%, respectively, P<0.01). The cumulative 3-year recurrence-free survival rate showed no statistical difference between the two groups. However, the cumulative 3-year survival rate was significantly higher in the non-portal hypertension group (82.8% vs. 53%, respectively, P=0.014). Conclusion: Indirectly diagnosed portal hypertension is correlated with the development of complications and poor prognosis after the surgical resection of HCC. (Korean J Hepatol 2006;12:553-561)
  • 3,335 View
  • 17 Download
Analysis of Survival and Factors Affecting the Survival after Surgical Resection of Peripheral Cholangiocarcinoma: 318 Cases in Single Institute
Gi Won Song , Sung Gyu Lee , Young Joo Lee , Kwang Min Park , Shin Hwang , Ki Hun Kim , Chul Soo Ahn , Deok Bog Moon , Tae Yong Ha , Dong Hwan Jung
Korean J Hepatol 2007;13(2):208-221.
Backgrounds/Aims
Although the survival rate after surgical resection of peripheral cholangiocarcinoma is low, surgical resection is only potentially curative therapy. The aim of this study is to evaluate clinicopathological factors affecting survival after surgical resection of peripheral cholangiocarcinoma. Methods: Between February 1990 and December 2005, surgical intervention with curative intent was performed on 318 patients and 292 patients underwent resection. We retrospectively analyzed survival data of 318 patients and clinicopathological factors affecting survival by reviewing the medical record. Results: Among the 292 cases of resection, curative resection with tumor-free margin (R0) has been resulted in 221 cases. The 1-, 3-, 5- and 10-year survival rate of R0 resection were 74.9, 46.9, 36.9 and 15.2%, respectively. The survival rate of patient undergoing R0 resection was significantly better than that of R1, R2 or nonresection. Multivariate analysis showed that curative resectability, macroscopic type of tumor and lymph node metastasis were statically significant independent prognostic factors. Conclusions: The survival after surgical resection of peripheral cholangiocarcinoma depends on curability of surgical resection, macroscopic type of tumor and status of lymph node. Particullary in R0 resection for intraductal growth type without lymph node metastasis, there is great chance for long-term survival. Surgical resection attaining tumor free margin should be attempted if liver function and general condition of patient are acceptable for hepatectomy. (Korean J Hepatol 2007;13:208-221)
  • 3,047 View
  • 21 Download